business backgrounder | industry
neighborhood has become a hotbed for medical research.
“Seattle is a biotech center of excellence,
and placing our inflammation research center
here allows us to attract top scientists and collaborate with high-quality partners,” said Mads
Krogsgaard Thomsen, Novo Nordisk’s, executive vice president and chief science officer.
Seattle was one of many cities Novo Nordisk was looking at for their research facility
in 2009 according to Beck. “What we found
here is a vibrant community of researchers
and companies that we wanted to be a part
of. We’ve developed some great partnerships
with surrounding research facilities and
businesses.”
With the expansion of their
Seattle office, Novo Nordisk hopes
to add the skills and talent they
procured towards Type 1 diabetes research. The expansion also
shows that Novo Nordisk will continue to be one of the anchors of
the Seattle biotech community.
“Novo Nordisk has been a trem e n d o u s p a r t n e r i n S e a t t l e ’s
biotech and life science community
since opening their inflammation
research headquarters in 2009. By selecting Seattle for
its North American diabetes research headquarters, they
will add dozens if not hundreds of new jobs to our region,
it also demonstrates that Seattle is a global leader in the
biotech and life science industry,” said Chris Rivera,
pres